Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial
| Autor: | Fernando Coutinho, Ana Rita Manhani, William S. Velasquez, Auro del Giglio |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Lymphoma Non-Hodgkin Prednisolone Cytarabine Antineoplastic Agents Hematology General Medicine Middle Aged Hodgkin Disease Treatment Outcome Drug Resistance Neoplasm Recurrence Antineoplastic Combined Chemotherapy Protocols Humans Drug Therapy Combination Female Cisplatin Topotecan Glucocorticoids Aged |
| Zdroj: | Acta haematologica. 112(3) |
| ISSN: | 0001-5792 |
| Popis: | We designed a phase I trial to assess the feasibility of the combination of topotecan, Ara-C, cisplatin and solumedrol (TOPOSHAP) in patients with relapsed or primary refractory lymphomas. We included 9 patients with mesurable non-Hodgkin’s (n = 8) and Hodgkin’s (n = 1) lymphomas. Level 1 consisted of topotecan 1.0 mg/m2/day, i.v., given on days 1–3, cisplatin 25 mg/m2/day, i.v., on days 1–3, Ara-C 500 mg/m2, i.v., on day 4, methylprednisolone 250 mg, i.v., on days 1–4. The regimen was repeated every 3–4 weeks. The maximum tolerated dose was already reached at level 1. G-CSF was added systematically after the 5th patient was included. The most significant toxicity in this trial was hematologic (all had neutropenia WHO grade 4 and 7 had grade 4 thrombocytopenia). Three patients had neutropenic fever. We observed two instances of WHO grade 3 and one of grade 4 diarrhea. Two patients achieved a complete response and 6 a partial response. We conclude that TOPOSHAP with G-CSF support is feasible and should be further studied in phase II studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|